Tirzepatide brought dual-receptor design into mainstream peptide research: one molecule engaging both the GIP and GLP-1 receptor pathways in laboratory models. It sits between semaglutide (single agonist) and retatrutide (triple agonist) in the design lineage, which makes it a fixture of comparative receptor-pathway studies.
What tirzepatide is
Tirzepatide is a synthetic 39-residue peptide (~4,814 Da) built on a GIP-like backbone, engineered with non-natural residues (including Aib) for enzymatic stability and carrying a C-20 fatty di-acid side chain for albumin binding — the same protraction strategy semaglutide uses, applied to a dual-receptor scaffold. In research models it engages GIP and GLP-1 receptors with different potencies, and that imbalance itself is a subject of mechanistic study.
Comparative research design
Because the mono/dual/triple agonists share design DNA, well-built studies often run them side-by-side: semaglutide as the GLP-1 baseline, tirzepatide for GIP synergy, retatrutide (see our research overview) for the glucagon axis, and a combination research blend where protocols call for it.
Handling
- Lyophilized: −20°C long-term, dark and dry.
- Reconstitution: like all acylated analogs, dissolve gently and patiently in bacteriostatic water for laboratory use — no aggressive agitation.
- Solutions: refrigerated, validated-window use, no freeze-thaw cycling.
Lot verification
- Identity: observed mass near ~4,814 Da confirms the full sequence with lipidation.
- Purity: ≥99% HPLC with method stated — a 39-residue lipidated synthesis is demanding, and honest documentation separates suppliers (our COA reading guide shows what to look for).
- Traceability: the vial’s lot number pulls its live certificate in the COA portal.
Research availability
Tirzepatide research material (10mg) — ≥99% HPLC-verified, mass-spec identity per lot, shipped same-day from Tulsa, Oklahoma.
Tirzepatide is supplied strictly for in vitro laboratory research — not for human or veterinary use.